Anti-MDR1 siRNA restores chemosensitivity in chemoresistant breast carcinoma and osteosarcoma cell lines

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2813-2820

  Perez, Jennifer ^a,b   Bardin, Christine ^a   Rigal, Chantal ^a   Anthony, Besse ^a   Rousseau, Raphaël ^b,c   Dutour, Aurelie ^a  

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Institute of Pediatric Hematology and Oncology   (France)

Author keywords

Carcinoma cell lines; Chemotherapy; Inhibition of multidrug resistance; Osteosarcoma cell lines; P Glycoprotein; siRNA

Indexed keywords

DOXORUBICIN; MESSENGER RNA; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CARCINOMA CELL; CELL PROLIFERATION; CHEMOSENSITIVITY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; METHOTREXATE; OSTEOSARCOMA; P-GLYCOPROTEIN; RNA, SMALL INTERFERING;

EID: 80051614348     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Chari RV: Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res 41: 98-107, 2008.
2. Martinez-Lacaci I, Garcia MP, Soto JL and Saceda M: Tumour cells resistance in cancer therapy. Clin Transi Oncol 9: 13-20, 2007.
3. Dean M, Hamon Y and Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 42: 1007-1017, 2001.
4. Toffoli G, Frustaci S, Tumiotto L, Talamini R, Gherlinzoni F, Picci P and Boiocchi M: Expression of MDR1 and GST-pi in human soft tissue sarcomas: relation to drug resistance and biological aggressiveness. Ann Oncol 3: 63-69, 1992.
5. Di Pietro A, Dayan G, Conseil G, Steinfels E, Krell T, Trompier D, Baubichon-Cortay H and Jault J: P-glycoprotein-mediated resistance to chemotherapy in cancer cells: using recombinant cytosolic domains to establish structure-function relationships. Braz J Med Biol Res 32: 925-939, 1999. (Pubitemid 29406571)
6. Hendrikse NH, Franssen EJ, van der Graaf WT, Meijer C, Piers DA, Vaalburg W and de Vries EG: 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein. Br J Cancer 77: 353-358, 1998. (Pubitemid 28044036)
7. Marie JP, Zittoun R and Sikic BI: Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78: 586-592, 1991.
8. Gomes CM, van Paassen H, Romeo S, Welling MM, Feitsma RI, Abrunhosa AJ, Botelho MF, Hogendoorn PC, Pauwels E and Cleton-Jansen AM: Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies. Nucl Med Biol 33: 831-840, 2006. (Pubitemid 44512136)
9. Fardel O, Lecureur V and Guillouzo A: The P-glycoprotein multidrug transporter. Gen Pharmacol 27: 1283-1291, 1996.
10. Tsuruo T, Iida H, Tsukagoshi S and Sakurai Y: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
11. Rogan AM, Hamilton TC, Young RC, Klecker RW Jr. and Ozols RF: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. (Pubitemid 14105761)
12. Sikic BI: Modulation of multidrug resistance: a paradigm for translational clinical research. Oncology (Williston Park) 13: 183-187, 1999.
13. Futscher BW, Foley NE, Gleason-Guzman MC, Meltzer PS, Sullivan DM and Dalton WS: Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance. Int J Cancer 66: 520-525, 1996. (Pubitemid 26176770)
14. Takara K, Sakaeda T and Okumura K: An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr Pharm Des 12: 273-286, 2006.
15. Motomura S, Motoji T, Takanashi M, Wang YH, Shiozaki H, Sugawara I, Aikawa E, Tomida A, Tsuruo T, Kanda N and Mizoguchi H: Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 91: 3163-3171, 1998. (Pubitemid 28193865)
16. Stierle V, Duca M, Halby L, Senamaud-Beaufort C, Capobianco ML, Laigle A, Jolles B and Arimondo PB: Targeting MDR1 gene: synthesis and cellular study of modified daunomycin-triplex-forming oligonucleotide conjugates able to inhibit gene expression in resistant cell lines. Mol Pharmacol 73: 1568-1577, 2008. (Pubitemid 351574846)
17. Scaggiante B, Morassutti C, Tolazzi G, Michelutti A, Baccarani M and Quadrifoglio F: Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett 352: 380-384, 1994.
18. Saad M, Garbuzenko OB and Minko T: Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomed 3: 761-776, 2008.
19. Wu H, Hait WN and Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63: 1515-1519, 2003. (Pubitemid 36373637)
20. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP and Fu LW: Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 5: 39-47, 2006. (Pubitemid 43234976)
21. Ueda K, Cardarelli C, Gottesman MM and Pastan I: Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987.
22. De Graaf D, Sharma RC, Mechetner EB, Schimke RT and Roninson IB: P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake. Proc Natl Acad Sci USA 93: 1238-1242, 1996. (Pubitemid 26052872)
23. Linn SC, Pinedo HM, Ark-Otte J, Hoekman VK, Honkoop AH, Vermorken JB and Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to chemotherapy. Int J Cancer 71: 787-795, 1997. (Pubitemid 27237200)
24. Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M and Scotto KW: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 5: 3352-3356, 1999.
25. Norris MD, De Graaf D, Haber M, Kavallaris M, Madafiglio J, Gilbert J, Kwan E, Stewart BW, Mechetner EB, Gudkov AV and Roninson IB: Involvement of MDR1 P-glycoprotein in multifactorial resistance to methotrexate. Int J Cancer 65: 613-619, 1996.
26. Lu ZJ and Mathews DH: Fundamental differences in the equilibrium considerations for siRNA and antisense oligodeoxynucleotide design. Nucleic Acids Res 36: 3738-3745, 2008. (Pubitemid 351917535)
27. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM and Macaulay VM: The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGFlR transcript. J Biol Chem 278: 15991-15997, 2003. (Pubitemid 36799718)
28. Gan HZ, Zhang GZ, Zhao JS, Zhang FC, Bu LS, Yang SJ, Piao SL, Du ZW, Gao S and Zheng DM: Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors. Chin Med J (Engl) 118: 893-902, 2005. (Pubitemid 40867459)
29. Bissett D, Kerr DJ, Cassidy J, Meredith P, Traugott U and Kaye SB: Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 64: 1168-1171, 1991.
30. Cagliero E, Ferracini R, Morello E, Scotlandi K, Manara MC, Buracco P, Comandone A, Baroetto PR and Baldini N: Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. Oncol Rep 12: 1023-1031, 2004.
31. Leveque D and Jehl F: P-glycoprotein and pharmacokinetics. Anticancer Res 15: 331-336, 1995.
32. Matsui Y, Kobayashi N, Nishikawa M and Takakura Y: Sequence-specific suppression of mdr1a/1b expression in mice via RNA interference. Pharm Res 22: 2091-2098, 2005. (Pubitemid 41821588)
33. Shen J, Liu J, Long Y, Miao Y, Su M, Zhang Q, Han H and Hao X: Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. Acta Biochim Biophys Sin (Shanghai) 41: 223-230, 2009.
34. Auguste DT, Furman K, Wong A, Fuller J, Armes SP, Deming TJ and Langer R: Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release 130: 266-274, 2008.
35. Niu XY, Peng ZL, Duan WQ, Wang H and Wang P: Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo. Int J Gynecol Cancer 16: 743-751, 2006.
36. Yoshizawa T, Hattori Y, Hakoshima M, Koga K and Maitani Y: Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 70: 718-725, 2008.
37. Garanger E, Boturyn D and Dumy P: Tumor targeting with RGD peptide ligands-design of new molecular conjugates for imaging and therapy of cancers. Anticancer Agents Med Chem 7: 552-558, 2007.